{"id":48574,"date":"2025-11-18T16:47:21","date_gmt":"2025-11-18T08:47:21","guid":{"rendered":"https:\/\/flcube.com\/?p=48574"},"modified":"2025-11-18T16:47:22","modified_gmt":"2025-11-18T08:47:22","slug":"gate-bioscience-closes-65m-series-b-to-advance-molecular-gates-to-clinic","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48574","title":{"rendered":"Gate Bioscience Closes $65M Series B to Advance Molecular Gates to Clinic"},"content":{"rendered":"\n

Gate Bioscience<\/strong> announced the close of its oversubscribed USD 65\u202fmillion Series B<\/strong> financing led by Forbion<\/strong> and joined by new investor Eli Lilly and Company<\/strong>, alongside existing backers Versant Ventures, Andreessen Horowitz (a16z) Bio + Health, GV, and ARCH Venture Partners. The proceeds will advance Gate\u2019s lead molecular gate<\/strong> programs into the clinic and expand its pipeline across inflammation and other therapeutic areas.<\/p>\n\n\n\n

Financing Details<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Gate Bioscience<\/td><\/tr>
Amount<\/strong><\/td>USD 65\u202fmillion (oversubscribed)<\/td><\/tr>
Round<\/strong><\/td>Series\u202fB<\/td><\/tr>
Lead Investor<\/strong><\/td>Forbion<\/td><\/tr>
New Investor<\/strong><\/td>Eli Lilly and Company<\/td><\/tr>
Existing Investors<\/strong><\/td>Versant Ventures, a16z Bio + Health, GV, ARCH Venture Partners<\/td><\/tr>
Use of Proceeds<\/strong><\/td>Advance lead molecular gate programs to IND; expand pipeline in inflammation and neurology<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Technology Profile<\/h2>\n\n\n\n